BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Stem Cells / iPS Cells

Cynata Completes Phase I Trial for CYP-001, Triggers Option Window for Fujifilm

By

It is official. Australian stem cell company Cynata Therapeutics has completed the world’s first Phase I trial involving an induced pluripotent stem cell (iPSC) derived therapeutic product. The landmark study involved the company’s lead product, CYP-001, an iPSC-derived mesenchymal stem cell (MSC) product that can be manufactured at therapeutic grade and at mass scale using Cynata’s Cymerus™ platform technology.

Next, the company will be initiating Phase II trials in graft-versus-host disease (GvHD), critical limb ischemia (CLI) and osteoarthritis, showcasing the power of Cynata’s platform technology to be leveraged across multiple indications. Osteoarthritis will be Cynata’s largest clinical trial to date and also one of the largest ever for an MSC product. [Read more…]

iPS Cells | Everything You Need To Know

By

Heard about iPS cells, but don’t know exactly what they are and what they can do? Read on to find out more.

In this article:

  1. What Are IPS Cells?
  2. How Are IPS Stem Cells Produced?
  3. What Are the Advantages of IPS Cells Over ES Cells?
  4. Are IPS Cells Similar to ES Cells?
  5. What Are the Risks of IPS Cell Use?
  6. What Are the Challenges in IPS Cell Research?
  7. Do IPS Cells Have the Potential for Medical Applications?

[Read more…]

New iPSC Lines Created for Clinical Development

By

iPSCs have been created using mRNA technologies, with cGMP control from donor screening, consenting, to skin punch, and throughout cell bank production.

iPSC production
1, iPSC colonies appear among fibroblasts; 2, isolated tight iPSC colony; 3, established iPSC 2D culture

SAN DIEGO, CA, USA, December 4, 2018 — After 3 years of cleanroom construction and 2 years of quality system establishment, Allele Biotech has produced its initial batch of 6 iPSC (induced pluripotent stem cells) lines that are ready for prime time. [Read more…]

iPSC Market Accelerated by Clinical Studies in Japan, Australia, UK, and U.S.

By

Growth of the iPSC market is supported by an increasing number of clinical studies that are investigating the therapeutic potential of iPSC-derived cell therapy products. Induced pluripotent stem cells (called iPSCs or iPS cells) are a type of stem cell that can become any cell within the human body, giving them enormous potential for use within regenerative medicine. [Read more…]

Stem Cell Treatment for Parkinson’s Disease

By

At least eight clinical trials worldwide and one physician-led study in Japan are exploring stem cells as a treatment approach to Parkinson’s disease. This research progress is critical, because the disease debilitates the body and causes tremors and numbness, loss of motor function, and stooping. Eventually, left untreated, Parkinson’s disease leads to death. The good news is, researchers are showing significant results in their studies on the link between stem cells and Parkinson’s disease.

In this article:

  1. An Introduction to Stem Cells
  2. What Are Stem Cells?
  3. What Is Parkinson’s Disease?
  4. How Does Stem Cell Therapy Work?
  5. How Can Stem Cells Help Heal This Condition?
  6. Clinical Study in Japan for Parkinson’s Disease
  7. Are We Close to a Widespread Solution?

[Read more…]

BioInformant's World-Class Clients